Patients treated with semaglutide (Ozempic / Wegovy) showed a 50% or greater reduction in the likelihood of both new alcohol use disorder (AUD) compared to patients treated with non GLP-1 anti-obesity or diabetes medications
Unlike FDA-approved versions, such as Ozempic, Wegovy, or Rybelsus, compounded semaglutide is custom-made by licensed pharmacies, often during shortages or when alternative dosing is needed
Together, these studies shifted medical consensus: obesity began to be treated as a chronic disease rather than a failure of willpower
While generally safe, GLP-1 medications are contraindicated for certain individuals
They concluded that Once-weekly tirzepatide 10 mg was associated with higher cost and greater reduction in A1c and weight vs semaglutide. IV
Un informe del 2024 publicado por The Lancet reflexion sobre el abordaje de la enfermedad: "Una simple pastilla o inyeccin sin duda ayudar a algunos pacientes, pero no puede ser la nica base para abordar las complejidades de la obesidad
